Sanofi $SNY Stock Holdings Increased by Mondrian Investment Partners LTD

Mondrian Investment Partners LTD lifted its stake in shares of Sanofi (NASDAQ:SNY) by 23.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,495,348 shares of the company’s stock after acquiring an additional 856,742 shares during the quarter. Sanofi accounts for about 3.4% of Mondrian Investment Partners LTD’s portfolio, making the stock its 6th largest position. Mondrian Investment Partners LTD owned 0.18% of Sanofi worth $217,845,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Prospera Financial Services Inc increased its holdings in Sanofi by 25.0% in the fourth quarter. Prospera Financial Services Inc now owns 13,685 shares of the company’s stock valued at $663,000 after buying an additional 2,737 shares during the last quarter. Coldstream Capital Management Inc. increased its holdings in Sanofi by 10.7% in the fourth quarter. Coldstream Capital Management Inc. now owns 10,131 shares of the company’s stock valued at $491,000 after buying an additional 978 shares during the last quarter. Jefferies Financial Group Inc. purchased a new position in Sanofi in the fourth quarter valued at $473,000. Lloyd Advisory Services LLC. purchased a new position in Sanofi in the fourth quarter valued at $187,000. Finally, Keudell Morrison Wealth Management purchased a new position in Sanofi in the fourth quarter valued at $596,000. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. Bank of America lowered Sanofi from a “buy” rating to a “neutral” rating in a report on Thursday, February 12th. Argus raised Sanofi to a “strong-buy” rating in a report on Monday, April 27th. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a report on Thursday, March 19th. Citigroup reissued a “neutral” rating on shares of Sanofi in a report on Monday, April 13th. Finally, Weiss Ratings raised Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, May 13th. Two investment analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and ten have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $51.00.

Sanofi Stock Performance

Shares of SNY stock opened at $44.29 on Friday. The stock’s 50-day moving average is $45.58 and its two-hundred day moving average is $47.23. The firm has a market cap of $108.02 billion, a price-to-earnings ratio of 12.37, a PEG ratio of 1.09 and a beta of 0.35. Sanofi has a 1 year low of $42.33 and a 1 year high of $53.03. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.22 and a current ratio of 1.01.

Sanofi Increases Dividend

The company also recently disclosed an annual dividend, which will be paid on Wednesday, June 3rd. Shareholders of record on Monday, May 4th will be issued a dividend of $2.4225 per share. The ex-dividend date of this dividend is Monday, May 4th. This is a positive change from Sanofi’s previous annual dividend of $2.04. This represents a dividend yield of 559.0%. Sanofi’s dividend payout ratio is 49.16%.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.